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Superdisintegrants are a key excipient used in immediate release formulations to 19 
promote fast tablet disintegration, therefore understanding the impact of superdisintegrant 20 
variability on product performance is important. The current study examined the impact of 21 
superdisintegrant critical material attributes (viscosity for sodium starch glycolate (SSG), 22 
particle size distribution (PSD) for croscarmellose sodium (CCS)) on their performance 23 
(swelling) and on drug dissolution using surface dissolution UV imaging. Acidic and basic 24 
pharmacopoeia (compendial) media were used to assess the role of varying pH on 25 
superdisintegrant performance and its effect on drug dissolution. A highly soluble 26 
(paracetamol) and a poorly soluble (carbamazepine) drug were used as model compounds and 27 
drug compacts and drug-excipient compacts were prepared for the dissolution experiments. 28 
The presence of a swelled SSG or CCS layer on the compact surface, due to the fast excipient 29 
hydration capacity, upon contact with dissolution medium was visualized. The swelling 30 
behaviour of superdisintegrants depended on excipient critical material attributes and the pH 31 
of the medium. Drug dissolution was faster in presence compared to superdisintegrant absence 32 
due to improved compact wetting or compact disintegration. The improvement in drug 33 
dissolution was less pronounced with increasing SSG viscosity or CCS particle size. Drug 34 
dissolution was slightly more complete in basic compared to acidic conditions in presence of 35 
the studied superdisintegrants for the highly soluble drug attributed to the increased excipient 36 
hydration capacity and the fast drug release through the swelled excipient structure. The 37 
opposite was observed for the poorly soluble drug as potentially the improvement in drug 38 
dissolution was compromised by drug release from the highly swelled structure. The use of 39 
multivariate data analysis revealed the influential role of excipient and drug properties on the 40 
impact of excipient variability on drug dissolution. 41 
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1. Introduction 45 
The identification and control of the critical material (i.e.excipient) properties are essential 46 
in the pharmaceutical Quality by Design (QbD) for the production of final products with the 47 
desirable critical quality attributes (Yu et al., 2014). Presence of superdisintegrants in oral solid 48 
dosage forms is essential for fast tablet disintegration and improved drug dissolution. Sodium 49 
starch glycolate (SSG)) and croscarmellose sodium (CCS) (semisynthetic polymers of starch 50 
and cellulose, respectively) are commonly used as superdisintegrants in tablet manufacturing. 51 
The main mechanism by which superdisintegrants promote tablet disintegration is swelling 52 
(Quodbach and Kleinebudde, 2016). Swelling refers to the volume expansion of the 53 
superdisintegrant particles upon contact with water (Quodbach and Kleinebudde, 2016). The 54 
swelling mechanism of SSG and CCS has been confirmed with the use of real-time magnetic 55 
resonance imaging (Quodbach et al., 2014). 56 
SSG and CCS are sodium salts and are present as a neutral form in acidic and ionized form 57 
in basic conditions. They derive from natural polymers after two main modification steps 58 
(carboxymethylation and crosslinking) of the natural polymer chains to improve excipient 59 
functionality (Quodbach and Kleinebudde, 2016). Firstly, carboxymethylation of the natural 60 
polymer backbone increases polymer hydrophilicity and allows water access into the excipient 61 
(Zhao and Augsburger, 2006). Secondly, as natural polymers are partially soluble, and their 62 
dissolution may increase the viscosity of the medium, crosslinking of the polymeric chains 63 
serves in decreasing the soluble content of the polymer. SSG is crosslinked through phosphate 64 
groups (Edge and Miller, 2005) while CCS through ester groups (Guest, 2005) (Figure 1). The 65 
superior performance of SSG and CCS as tablet disintegrants, compared to native polymers, is 66 
attributed to these two modification steps. 67 
The extensive and fast swelling of SSG and CCS is demonstrated by the increase in their 68 
volume median diameter (average volumetric size) upon contact with water (123 μm upon 69 
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contact with water vs 35 μm of the dry excipient powder for SSG, 92 μm upon contact with 70 
water vs 45 μm of the dry excipient powder for CCS) and the amount of liquid water uptake 71 
(16 g/g and 10 g/g in 120 sec for SSG and CCS, respectively) (Zhao and Augsburger, 2005). 72 
The differences in the swelling capacity of SSG and CCS, despite their similar structure, have 73 
been attributed to the difference in their dimensional expansion (3-dimensional swelling for 74 
SSG, 2-dimensional swelling for CCS) (Rojas et al., 2012; Zhao and Augsburger, 2005) and 75 
their different crosslinking (the phosphate group of SSG, compared to the ester group of CCS, 76 
allows for more spacing between the polymeric chains) (Rojas et al., 2012). Molecular 77 
properties (degree of substitution, degree of crosslinking), particle properties (particle size 78 
distribution (PSD)) and level have been identified as potential critical material attributes for 79 
SSG and CCS affecting product performance (Zarmpi et al., 2017). Increasing the degree of 80 
substitution of SSG and CCS results in faster water uptake and excipient swelling, however 81 
optimum values need to be defined as high degrees of carboxymethylation may result in an 82 
increase in the viscosity of the medium (Zarmpi et al., 2017). Extensive swelling and faster 83 
disintegration have been reported when increasing the degree of crosslinking, particle size or 84 
level in formulations for SSG and CCS (Zarmpi et al., 2017). 85 
The biopharmaceutical implications of superdisintegrant presence or variability on product 86 
performance are not well known. Gastrointestinal factors may impact the performance of 87 
superdisintegrants with pH being the most influential due to the ionization pattern of SSG and 88 
CCS. The hydration capacity of the acid excipient form in acidic media is lower compared to 89 
the ionized excipient form in basic media (acidic and basic media are defined based on the 90 
physiological pH range (Sjogren et al., 2014)) leading to reduced swelling in acidic conditions 91 
(Zhao and Augsburger, 2005). The % increase in the volume media diameter in water and 0.1 92 
N HCl pH 1 was 251% and 43%, respectively for SSG and 104% and 51%, respectively for 93 
CCS (Zhao and Augsburger, 2005). The impact of superdisintegrants on product performance 94 
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relates also to drug properties. Interaction of cationic drugs with the carboxylic group of CCS 95 
can affect routine drug analysis. Loss of the active pharmaceutical ingredient (API) from a 96 
tablet formulation containing CCS during sample treatment can be expected, as low % recovery 97 
of drugs (metformin (Huang et al., 2006), escitalopram (Larsen and Melander, 2012)) from 98 
solutions in presence of CCS have been reported due to charge drug-excipient interactions. 99 
Delay in the dissolution of cationic drugs from immediate release tablets containing SSG and 100 
CCS has also been attributed to electrostatic drug-excipient interactions (Balasubramaniam et 101 
al., 2008). 102 
Current approaches for assessing superdisintegrant performance and variability include the 103 
determination of: disintegration time of formulations, water uptake of powders/tablets, 104 
swelling volume of superdisintegrants, exerted force (force inside tablets that has to surpass 105 
the cohesive tablet forces) during tablet disintegration, dissolution rate of drugs, and size of 106 
generated particles after tablet disintegration (Quodbach and Kleinebudde, 2016). Real – time 107 
surface dissolution UV imaging is currently used in the pharmaceutical field providing 108 
additional information on disintegration/dissolution phenomena. UV dissolution imaging can 109 
be valuable in QbD approaches as it provides a mechanistic understanding into the surface 110 
events at the initial stages of drug dissolution and in early drug discovery to characterize new 111 
drug candidates (Kuentz, 2015; Niederquell and Kuentz, 2014). This technique utilizes a 112 
compact flow-cell integrated with a UV-vis camera and a pump for the infusion of the 113 
dissolution medium under laminar flow (Østergaard et al., 2014). The measured transmittance 114 
of light through the cell allows the characterization of the dissolving substance spatially and 115 
temporally and is useful for the identification of drug intrinsic dissolution rates, surface 116 
swelling/disintegration/dissolution phenomena, concentration gradients and 117 
microenvironmental pH changes (Gordon et al., 2013). Insights in the dissolution behaviour of 118 
APIs (Østergaard et al., 2014), excipients (Pajander et al., 2012) and their interplay (Colombo 119 
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et al., 2015; Hiew et al., 2018) have been provided with the use of real-time surface dissolution 120 
imaging. 121 
The aims of this study were to assess the swelling performance of superdisintegrants with 122 
different potential critical material attributes and the impact and criticality of superdisintegrant 123 
variability on drug dissolution. Excipient characterization and drug dissolution studies in 124 
absence and presence of excipients were performed with the use of real-time surface dissolution 125 
UV imaging. The impact of excipient variability on excipient swelling and drug dissolution 126 
was studied by selecting three brands of SSG of different viscosity type and two brands of CCS 127 
of different PSD. A highly [paracetamol; Biopharmaceutical Classification System (BCS) class 128 
III (Kalantzi et al., 2006)] and a poorly soluble (carbamazepine; BCS class II (Kovacevic et 129 
al., 2009)) drug were used to assess the interplay of excipient variability and drug 130 
characteristics on drug dissolution. Studies were performed in acidic and basic compendial 131 
media to assess the role of pH on superdisintegrant swelling and drug dissolution. 132 
2. Materials and Methods 133 
2.1. Materials 134 
APIs: Paracetamol (PRC, form I) was obtained from Fischer Scientific (UK). 135 
Carbamazepine (CBZ, form III) was purchased from Fagron (UK). Excipients: SSG brands: 136 
Glycolys LV [low viscosity (viscosity of aqueous solution at 60 min = 10.8 cP)] and Glycolys 137 
[high viscosity (viscosity of aqueous solution at 60 min = 20.9 cP)] (Roquette, France),). 138 
Explotab CLV [low viscosity (viscosity of aqueous solution at 60 min = 12.7 cP)] (JRS Pharma, 139 
USA) and CCS brands: AcDiSol [low particle size (d90 = 74.2 μm)] (FMC, USA), Primellose 140 
[high particle size (d90 = 109.8 μm)] (DFE Pharma, Germany) were obtained from the specified 141 
sources. Chemicals: Hydrochloric acid 36.5–38%, HPLC grade methanol were obtained from 142 
Sigma-Aldrich (UK). Sodium chloride, sodium hydroxide, potassium phosphate monobasic 143 
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were obtained from Fisher Scientific (UK). Water was ultra-pure (Milli-Q) laboratory grade. 144 
Filters: Polytetrafluoroethylene (PTFE) 13 mm filter 0.45 μm pore size were purchased from 145 
Fisher Scientific (UK). 146 
2.2. Instrumentation 147 
Sartorius BP 210 D balance (Sartorius UK Ltd, UK), Mettler Toledo SevenCompact S210 148 
pH meter (Mettler Toledo, Switzerland), Vortex-Genie 2 vortex mixer (Scientific Industries 149 
Inc, USA), Agilent Technologies 1100 series HPLC system, (quaternary pump (G1311A), 150 
autosampler (G1313A), thermostatted column compartment (G1316A), diode array detector 151 
(G1329A) and a Chemstation software (Agilent Technologies, USA), Actipix SDI300 152 
dissolution imaging system (Paraytec Ltd, UK) with an Actipix flow-through dissolution 153 
cartridge CADISS-2, Quickset Minor® torque screwdriver (Torqueleader, UK), Actipress 316 154 
stainless steel press (Paraytec LtD, UK). 155 
2.3. Methods 156 
2.3.1. Media used for in vitro dissolution studied 157 
Compendial media (0.1 N HCl pH 1, phosphate buffer pH 6.8) were prepared according to 158 
the method described in the European Pharmacopeia (Ph.Eur., 2014). 159 
2.3.2. Preparation of compacts 160 
For the excipient characterization, 20 mg of each excipient were poured into the sample 161 
cup (stainless steel cylinder, inner diameter: 2 mm, height: 2.4 mm) and compacted using a 162 
manual press at a constant torque of 75 cNm for 5 min (Pajander et al., 2012). For the 163 
dissolution studies, compacts of pure APIs (paracetamol (PRC), carbamazepine (CBZ)) and 164 
compacts of superdisintegrants with the APIs were prepared. 10 mg of API (PRC, CBZ) were 165 
poured into the sample cup and compacts of pure API (drug compacts) were prepared using a 166 
manual press at a constant torque of 75 cNm for 5 min (Pajander et al., 2012). 10 mg of API 167 
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and 1 mg (2% w/w) of each excipient were prepared by vortexing (3 min) and poured into the 168 
sample cup. Compacts of superdisintegrants with APIs (drug-excipient compacts) were 169 
prepared using a manual press at a constant torque of 75 cNm for 5 min (Pajander et al., 2012). 170 
2.3.3. In vitro real-time surface dissolution UV imaging 171 
Real-time surface dissolution UV Imaging was performed using an Actipix SDI300 surface 172 
dissolution imaging system with an Actipix flow-through-type dissolution cartridge. The flow 173 
cell consisted of an Actipix cartridge fitted with a quartz cell (7 mm height, 4 mm width, 62 174 
mm length) and a polyetheretherketone (PEEK) sample holder. The light source was a pulsed 175 
xenon lamp and a band-pass filter (detection wavelength ± 10 nm) was used for the selection 176 
of the wavelength of interest. Dissolution medium was infused into the cell through a syringe 177 
pump. A temperature control unit was used to maintain constant temperature. The detection 178 
area of the UV imager was 9 mm × 7 mm (1280 pixel × 1024 pixel) with a pixel size of 7 μm 179 
× 7 μm. Detailed representation of the instrument has been previously presented (Long et al., 180 
2019; Østergaard et al., 2014). 181 
For the excipient characterization, experiments were performed at 254 nm using stagnant 182 
conditions for 5 min at 37 °C in 0.1 N HCl pH 1 and phosphate buffer pH 6.8. In vitro drug 183 
dissolution experiments from drug compacts and drug-excipient compacts were performed at 184 
280 nm using 1 mL/min flow rate for 20 min at 37 °C in 0.1 N HCl pH 1 and phosphate buffer 185 
pH 6.8. For both the excipient characterization experiments and in vitro drug dissolution 186 
studies, dark (10 s duration with the lamp turned off) and reference (10 s duration with the lamp 187 
turned on) images were recorded with the flow cell filled with dissolution medium in absence 188 
of compact. Data collection was initiated and after 60 s data recording was paused and the 189 
compacts were introduced into the cell. The system was flushed with dissolution media to avoid 190 
presence of air bubbles in the flow cell and data collection was resumed. Pixel intensities within 191 
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a designated quantification region were converted into absorbance values using the Actipix 192 
D100 software version 1.8.50805 (Paraytec Ltd, UK). In the in vitro drug dissolution 193 
experiments, the presence of the swelling excipients (SSG and CCS brands) in the 194 
quantification regions of the UV image resulted in increased scattering or physical blockage of 195 
light (Long et al., 2019). In these cases, the eluting sample was collected at 1 min intervals and 196 
the effluent samples were filtered through PTFE 0.45 μm pore size filters and analysed by 197 
HPLC. Filter adsorption studies were prior performed in triplicate for each drug and confirmed 198 
that there were no adsorption issues for the studied drugs on the filters used. All experiments 199 
were performed in triplicate. 200 
2.3.4. Chromatographic conditions 201 
Dissolution samples (effluent collection) were analysed by HPLC. Analytical HPLC 202 
procedures were modifications of already published methods for PRC (Gao et al., 2014) and 203 
CBZ (Vertzoni et al., 2006). A reversed-phase Spherisorb (Waters) C18 column (250 × 4.6 204 
mm, 5 μm) was used for both drugs. For PRC, the mobile phase consisted of methanol and 205 
water 20:80 (v/v) and the temperature was kept constant at 20 °C. The injection volume was 206 
20 μL and the detection wavelength was at 257 nm. For CBZ, the mobile phase was composed 207 
of methanol and water 60:40 (v/v) and the temperature was kept at 25 °C. The injection volume 208 
was 100 μL and the detection wavelength was at 285 nm. The flow rate was set at 1 mL/min 209 
for both drugs (isocratic flow). The elution times were 6 min and 4 min for PRC and CBZ, 210 
respectively. Drug quantification was made based on calibration curves. Standards were 211 
prepared from concentrated stock solution of drug dissolved in MeOH (PRC: 2 mg/mL, CBZ: 212 
1 mg/mL). The range of the calibration curves were 10 – 300 μg/mL and 0.5 -50 μg/mL for 213 
PRC and CBZ, respectively. 214 
2.3.5. Treatment of in vitro dissolution data 215 
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For the characterization of the swelling superdisintegrant behaviour, quantitative data of 216 
excipient concentration gradients cannot be obtained due to i. the insolubility of the studied 217 
polymers and ii. the fact that the high absorbance values recorded may be attributed to 218 
absorbance or scattering of light by the swelled polymer or physical blockage of light by 219 
undissolved polymer particles (Pajander et al., 2012). Only qualitative information of the rate 220 
and extent of swelling can be obtained by the absorbance gradients as a function of distance 221 
from the center of the sample cup. Absorbance values (Abs) were automatically calculated 222 
from pixel intensities using the Actipix D100 software version 1.8.50805 (Paraytec Ltd, UK) 223 
(zone dimensions of the images: 4.6 mm × 1.3 mm). The classification gradient maps (image 224 
gradients where changes of the z variable along the x and y directions are illustrated by changes 225 
in colour) depicting the swelling behaviour (absorbance values as a function of distance from 226 
the center of the sample cup) of the studied SSG and CCS brands in 0.1 N HCl pH 1 and 227 
phosphate buffer pH 6.8 were generated using SigmaPlot 13.0 (Systat Software Inc, USA). The 228 
cumulative % of drug dissolved was calculated based on the measured drug concentration in 229 
the samples (based on the HPLC analytical data) and the amount of drug in the compact. The 230 
dissolution profiles of the cumulative % of drug dissolved as a function time were constructed. 231 
Drug dissolution rates (μg/min) at each 1 min interval over the duration of the experiments 232 
were calculated based on the measured drug concentration in the samples (based on the HPLC 233 
analytical data) and the known flow rate of the dissolution experiments. Graphs depicting drug 234 
dissolution rates as a function of time (at 1 min intervals) were constructed and the standard 235 
deviation (SD) of the dissolution rates was presented in the midterm point of the sampling 236 
intervals. 237 
The area under the curve (AUC) of the dissolution profiles up to last experimental time (20 238 
min), calculated using the method of trapezoids, was used for the characterization of drug 239 
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dissolution. The Relative Effect (RE) of each superdisintegrant on drug dissolution was 240 
calculated based on equation 1: 241 
𝑅𝐸 =  
(𝐴𝑈𝐶𝑇− 𝐴𝑈𝐶𝐶)
𝐴𝑈𝐶𝐶
 𝑥 100 equation 1 242 
where 𝐴𝑈𝐶𝑐 and 𝐴𝑈𝐶𝑇 are the areas under the curve of the dissolution profiles of the 243 
control and test compact, respectively. Two sets of comparisons were performed. In the first 244 
set (set 1), the differences in drug dissolution between drug compacts and drug-excipient 245 
compacts in each medium were examined taking the AUCs of the dissolution profiles of the 246 
drug compact and the drug-excipient compact as control and test dissolution profiles, 247 
respectively. In the second set (set 2), differences in drug dissolution within acidic and basic 248 
conditions in each drug-excipient compact were investigated taking the AUCs of the 249 
dissolution profiles in acidic and basic conditions as the control and test dissolution profiles, 250 
respectively. The risk assessment of the impact of excipients on drug dissolution was evaluated 251 
by setting reference range criteria of -20% - 25% (FDA, 2002) on the REs of excipients on the 252 
AUCs of the dissolution profiles (this range was selected as a similar range is set in order to 253 
assess differences in drug exposure after oral administration; i.e. in bioequivalence studies). 254 
REs of excipients on the AUCs of the dissolution profiles outside these values (REs < -20% or 255 
REs > 25%) were considered potentially critical for oral drug performance. 256 
2.3.6. Multivariate data analysis of in vitro dissolution data 257 
Excipient REs on drug dissolution were correlated to excipient critical material attributes 258 
(viscosity for SSG, PSD for CCS), drug aqueous solubility (Drugaq.sol.) and medium (acidic, 259 
basic) characteristics by multiple linear regression (MLR) using the XLSTAT software 260 
(Microsoft, USA). Two models for the REs of excipients on the AUCs of the dissolution 261 
profiles in presence of SSG (Model 1) and CCS (Model 2) were constructed. The evaluated 262 
variables for both models were all categorical and included: i. drug aqueous solubility 263 
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(Drugaq.sol.) [0: poorly soluble, 1: highly soluble; based on the compound’s BCS 264 
(Biopharmaceutical Classification System) classification (highly soluble: BCS Class I and III; 265 
poorly soluble: BCS Class II and IV) (FDA, 2017)], ii. medium (0: acidic, 1: basic), iii. 266 
excipient brand (0: low excipient property, 1: high excipient property; based on the measured 267 
viscosity values of SSG and the measured particle size (d90) of the CCS brands). Excipient REs 268 
on the AUCs of the dissolution profiles (set 1, section 2.3.5) were used as the response. The 269 
selected interaction terms included each excipient brand combined with each drug aqueous 270 
solubility and medium characteristics (acidic, basic). The generated MLR models were 271 
assessed in terms of goodness of fit (R2) and variance inflation factor (VIF). High R2 values 272 
and VIF values < 5 were indications of successful models with absence of multicollinearity 273 
among the independent variables (Montgomery and Peck, 1992). Standardized coefficients 274 
were used to show the direction (positive or negative) and extent of each variable on the 275 
response. The significance of the variables was assessed by the p values (p < 0.05 were 276 
considered the most significant in the model (Montgomery and Peck, 1992)). A 95% 277 
confidence interval was used. 278 
3. Results and Discussion 279 
3.1.  Characterization of the swelling behaviour of superdisintegrants using 280 
real-time surface dissolution UV Imaging 281 
The studied excipient types and brands have been previously characterized in terms of 282 
viscosity for SSG and PSD for CCS (Zarmpi et al., 2019). The viscosity after 60 min of the 283 
aqueous dispersions of Glycolys LV (10.8 cP) and Explotab CLV (12.7 cP) was lower 284 
compared to Glycolys (20.9 cP), due to their higher degree of crosslinking and lower soluble 285 
material content (Shah and Augsburger, 2001). Differences in the PSD of the CCS brands were 286 
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identified, as AcDiSol comprised of smaller particles (d10: 12.8 μm, d50: 31.9 μm, d90: 74.2 287 
μm) compared to Primellose (d10: 21.8 μm, d50: 52.2 μm d90: 109.8 μm). 288 
Surface dissolution UV imaging was used to study the swelling performance of SSG and 289 
CCS in simple buffers and UV images of the excipient swelling upon contact with the 290 
dissolution media are presented in Supplementary Figure 1. The swelling behaviour of the 291 
studied superdisintegrants as a function of time and distance from the centre of the sample cup 292 
in 0.1 N HCl pH 1 is presented in Figure 2. Intense signals at the compact location are 293 
indications of dense swollen polymeric structures (Colombo et al., 2015), as the high 294 
absorbance recorded are attributed to light scattering by the swelled superdisintegrants or 295 
physical blockage of light by undissolved excipient particles (as explained in section 2.3.5.). 296 
The fast excipient swelling was demonstrated as all the studied superdisintegrants swelled at a 297 
distance of 1.2 mm from the centre of the sample cup at approximately 20 – 40 s irrespective 298 
of excipient type or brand. For SSG, Glycolys exhibited lower absorbance values (Abs ≈ 1.0 – 299 
1.2 AU) compared to Glycolys LV and Explotab CLV (Abs ≈ 1.2 – 1.6 AU) probably due to 300 
the higher soluble content of high viscosity brands (Shah and Augsburger, 2001). For CCS, the 301 
higher absorbance values of Primellose (Abs ≈ 1.4 – 1.6 AU) compared to AcDiSol (Abs ≈ 1.0 302 
– 1.2 AU) can be attributed to the pronounced physical blockage of light by larger particles 303 
(Van Eerdenbrugh et al., 2011). 304 
The swelling behaviour of the studied superdisintegrants as a function of time and 305 
distance from the centre of the sample cup in phosphate buffer pH 6.8 is presented in Figure 306 
3. Slightly faster excipient swelling in phosphate buffer pH 6.8 (< 20 s) was observed compared 307 
to 0.1 N HCl pH 1 (20 – 40 s) explained by the higher liquid uptake (0.1 N HCl pH 1: 308 
approximately 5 g/g liquid uptake by SSG and CCS after 2 min, water: 18 g/g and 10 g/g liquid 309 
uptake by SSG and CCS, respectively after 2 min (Zhao and Augsburger, 2005)) and excipient 310 
swelling of the ionized excipient form in basic media (Zhao and Augsburger, 2005). The 311 
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absorbance values of the studied brands were lower in phosphate buffer pH 6.8 (SSG brands: 312 
0.6 – 1.2 AU, CCS brands: 1.0 – 1.4 AU) compared to 0.1 N HCl pH 1 (SSG brands: 1.0 – 1.6 313 
AU, CCS brands: 1.0 – 1.6 AU). We hypothesize that the lower absorbance values in the basic 314 
compared to the acidic medium relate to the higher excipient swelling of the ionized excipient 315 
forms in phosphate buffer pH 6.8 (as compared to the unionized excipient forms in 0.1 N HCl 316 
pH 1), as the higher spacing of the swelled polymeric chains (Rojas et al., 2012) could decrease 317 
the scattering or physical blockage of light. Differences in the absorbance values are not 318 
observed within the studied SSG brands (Abs ≈ 0.6 – 1.0 AU). For CCS, lower absorbance 319 
values were observed for AcDiSol (Abs ≈ 1.0 – 1.2 AU) attributed to its lower particle size 320 
compared to Primellose (Abs ≈ 1.2 – 1.4 AU) [24]. The lower absorbance values of the SSG 321 
compared to the CCS brands in phosphate buffer pH 6.8 can indicate a more extensive swelling 322 
by SSG, due to the differences in the dimensional expansion (3 dimensional swelling 323 
(semispherical particles) for SSG and 2 dimensional swelling (fibrous particles) for CCS upon 324 
contact with simulated intestinal fluid have been reported (Rojas et al., 2012)) and type of 325 
crosslinking (phosphate groups for SSG, ester group for CCS) between the two excipient types 326 
(Rojas et al., 2012). The observed differences in excipient performance in the studied media 327 
indicate that differences in tablet disintegration between the stomach and the small intestine 328 
are anticipated (due to the differences in the pH of these two compartments) and could 329 
potentially implicate product performance and drug bioavailability. 330 
3.2. Impact of SSG variability on drug dissolution using surface dissolution UV 331 
Imaging 332 
3.2.1. Highly soluble drug (PRC) 333 
The dissolution profiles and dissolution rates of PRC from drug compacts (control) and 334 
drug-SSG compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented in Figure 335 
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4. Approximately 5% of PRC dissolved from the drug compact in 20 min in both media. The 336 
% of drug dissolved in 20 min from the drug-SSG compacts was increased in 0.1 N HCl pH 1 337 
(21%, 23% and 25% of drug dissolved in the presence of Glycolys LV, Explotab CLV and 338 
Glycolys, respectively) and in phosphate buffer pH 6.8 (22%, 27% and 21% of drug dissolved 339 
in the presence of Glycolys LV, Explotab CLV and Glycolys, respectively). The dissolution 340 
rate of PRC from drug compacts was slow during the experiments in both media studied 341 
(dissolution rates of approximately 20 μg/min and 17 μg/min in 0.1 N HCl pH 1 and phosphate 342 
buffer pH 6.8 at 20 min, respectively). Drug dissolution from drug-SSG compacts was faster 343 
compared to drug dissolution from drug compacts in the studied media, especially at early time 344 
points (1 – 5 min), as indicated by the increased dissolution rates of PRC in excipient presence 345 
(dissolution rates of approximately 200 μg/min from compacts containing Glycolys LV, 346 
Explotab CLV and Glycolys at 5 min in both media). This could be explained by the fast 347 
excipient hydration and swelling (excipient swelling at a distance of 1.2 mm from the centre 348 
of the sample cup within the first 40s, section 3.1) improving compact wetting (Onuki et al., 349 
2018). Compact disintegration may also have contributed to the faster drug dissolution from 350 
drug-excipient compacts compared to drug compacts, as spread particles around the compact 351 
surface were observed after the end of each experiment only for the drug-excipient compacts. 352 
Comparison of the AUCs of the dissolution profiles revealed that drug dissolution was more 353 
complete from the drug-excipient compacts compared to drug dissolution from the drug 354 
compacts (REs > 25%) (Figure 5a). Differences in PRC dissolution from drug-SSG compacts 355 
in acidic and basic conditions for the studied SSG brands were not observed (REs of 356 
approximately 5%, 20% and -20% for Glycolys LV, Explotab CLV and Glycolys, 357 
respectively). The observed minor REs indicate that the pH-depended swelling performance of 358 
SSG (section 3.1) may not significantly affect the dissolution of a highly soluble drug between 359 
acidic and basic conditions. 360 
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3.2.2. Poorly soluble drug (CBZ) 361 
The dissolution profiles and dissolution rates of CBZ from drug compacts (control) and 362 
drug-SSG compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented in Figure 363 
6. Approximately 0.1% of CBZ dissolved from the drug compact in 20 min in both 0.1 N HCl 364 
pH and phosphate buffer pH 6.8. In 0.1 N HCl pH 1, 2.3%, 1.6% and 1.3% of drug dissolved 365 
in 20 min in presence of Glycolys LV, Explotab CLV and Glycolys, respectively. The % of 366 
CBZ dissolved in excipient presence in phosphate buffer pH 6.8 in 20 min was similar between 367 
the different drug-excipient compacts (approximately 1.5% of CBZ dissolved from drug-368 
excipient compact containing Glycolys LV, Explotab CLV, Glycolys). The rate of drug 369 
dissolution from the drug compact was slow in both sets of media (dissolution rates of 370 
approximately 0.5 μg/min at 20 min in 0.1 N HCl pH 1 and phosphate buffer pH 6.8). CBZ 371 
dissolution was faster in SSG presence, especially at early time points (1 - 5 min), potentially 372 
due to the fast excipient swelling or compact disintegration (as explained in the case of PRC). 373 
In 0.1 N HCl pH 1, the dissolution rates of CBZ from drug-excipient compacts were 13 μg/min, 374 
8.6 μg/min and 6.2 μg/min at 5 min in presence of Glycolys LV, Explotab CLV and Glycolys, 375 
respectively. The lower amount of drug dissolved in presence of Glycolys compared to the low 376 
viscosity brands (Glycolys LV, Explotab CLV) may be explained by the increase in the 377 
viscosity of the gel around the compact by high viscosity Glycolys (Quodbach and 378 
Kleinebudde, 2016). The pronounced differences in the CBZ dissolution rates from compacts 379 
containing the low and high viscosity SSG brands are diminished at late points. Faster CBZ 380 
dissolution in presence compared to absence of excipient was also observed in phosphate buffer 381 
pH 6.8, with the dissolution rates from the three drug-excipient compacts being similar (CBZ 382 
dissolution rates of approximately 7 μg/min at 5 min in presence of the three studied SSG 383 
brands). CBZ dissolution in presence of excipient was more complete compared to the 384 
excipient absence (REs > 25%) (Figure 5a). Differences in drug dissolution from drug-385 
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excipient compacts between acidic and basic conditions were observed. For the low viscosity 386 
brands (Glycolys LV, Explotab CLV), the REs on the AUCs of the dissolution profiles between 387 
acidic and basic conditions were negative (REs of -45% and -20% for Glycolys LV and 388 
Explotab CLV, respectively), indicating that the improvement in CBZ dissolution is less 389 
pronounced in phosphate buffer pH 6.8 compared to 0.1 N HCl pH 1. As superdisintegrants 390 
swell more extensively in basic compared to acidic conditions due to their ionization (Rojas et 391 
al., 2012), the presence of a highly swelled layer on top of the sample cup may add a physical 392 
or diffusive barrier for the release of poorly soluble drugs (Long et al., 2019), despite the faster 393 
polymer water uptake in basic conditions (as explained previously in section 3.1). The swelling 394 
of the high viscosity Glycolys is as well more extensive in basic compared to acidic conditions, 395 
however comparison of CBZ dissolution profiles from compacts containing Glycolys between 396 
basic and acidic media reveal slightly more complete dissolution in phosphate buffer pH 6.8 397 
(REs of 30%). This positive RE on the AUCs of the dissolution profiles may relate to the 398 
gelling effects of Glycolys (Quodbach and Kleinebudde, 2016) and the slower CBZ dissolution 399 
observed in 0.1 N HCl pH 1 (compared to the other two excipient brands). 400 
3.3. Impact of CCS variability on drug dissolution using surface dissolution UV 401 
Imaging 402 
3.3.1. Highly soluble drug (PRC) 403 
The dissolution profiles and dissolution rates of PRC from drug compacts (control) and 404 
drug-CCS compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented in Figure 405 
7. A higher % of drug dissolved in 20 min was observed in excipient presence in 0.1 N HCl 406 
pH 1 (AcDiSol: 23%, Primellose: 14%) and phosphate buffer pH 6.8 (AcDiSol: 25%, 407 
Primellose: 26%) compared to the % of PRC dissolved from the drug compact (5% of drug 408 
dissolved in 20 min). Faster drug dissolution was revealed in excipient presence compared to 409 
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excipient absence in both media which may be explained by the enhancement in compact 410 
wetting or compact disintegration due to the hydrophilicity and swelling of CCS (Quodbach 411 
and Kleinebudde, 2016). Differences in drug dissolution rates from the studied drug-CCS 412 
compacts were observed at early time points in 0.1 N HCl pH 1 as the dissolution rate of PRC 413 
was lower in presence of Primellose (98 μg/min of drug dissolved at 5 min) compared to 414 
AcDiSol (182 μg/min of drug dissolved at 5 min), probably due to the presence of larger 415 
excipient particles (Primellose) on top of the compact surface (section 3.1). In phosphate buffer 416 
pH 6.8 similar drug dissolution was observed between the drug-CCS compacts containing 417 
AcDiSol and Primellose (dissolution rates of approximately 200 μg/min in presence of both 418 
CCS brands at 5 min). At late time points, the dissolution rate of PRC gradually decreased in 419 
presence of the CCS brands in both media and any differences in drug dissolution between the 420 
studied CCS brands were diminished. Comparison of the AUCs of the dissolution profiles of 421 
the drug and drug-CCS compacts revealed significantly more complete dissolution from 422 
compacts containing excipient (REs > 25%) (Figure 5b). Differences in drug dissolution from 423 
drug-AcDiSol compacts between acidic and basic conditions were not observed, as revealed 424 
by the REs of AcDiSol on the AUCs of the dissolution profiles between acidic and basic 425 
conditions (RE = 10%). Drug dissolution from the drug-Primellose compacts was significantly 426 
more complete in phosphate buffer pH 6.8 compared to 0.1 N HCl pH (RE = 97%), potentially 427 
due to the presence of larger excipient particles in 0.1 N HCl pH 1.  428 
3.3.2. Poorly soluble drug (CBZ) 429 
The dissolution profiles and dissolution rates of CBZ from drug compacts and drug-CCS 430 
compacts in 0.1 N HCl pH 1 and phosphate buffer pH 6.8 are presented in Figure 8. CBZ 431 
dissolution reached approximately 1.8% and 1.5% from compacts containing AcDiSol and 432 
Primellose, respectively in 0.1 N HCl pH 1 and 1.3% and 1.0% in phosphate buffer pH 6.8. 433 
The fast excipient swelling at early time points (section 3.1) resulted in faster drug dissolution 434 
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from drug-CCS compacts compared to the drug compacts in both sets of media, especially at 435 
early time points. Drug dissolution was slower in presence of Primellose (7 μg/min and 5 436 
μg/min in acidic and basic conditions, respectively) compared to AcDiSol (9 μg/min and 7 437 
μg/min in the acidic and basic medium, respectively), probably due to the presence of larger 438 
excipient particles (Primellose) on top of the compact surface (section 3.1). Differences in drug 439 
dissolution between the studied brands were smaller at late time points. In presence of 440 
excipient, drug dissolution was significantly more complete compared to the control sample in 441 
both experimental conditions (REs > 25%) (Figure 5b). The enhancement in CBZ dissolution 442 
by CCS presence was more pronounced in acidic compared to basic conditions (REs on the 443 
AUCs of the dissolution profiles between acidic and basic conditions of -30% and -20% for 444 
AcDiSol and Primellose, respectively). The faster water uptake of the excipients in basic media 445 
(Rojas et al., 2012) would be expected to result in faster drug dissolution due to the improved 446 
compact wetting , however this is not observed as potentially the presence of a swelled layer 447 
on top of the compact surface created a physical or diffusive barrier delaying drug release 448 
(Long et al., 2019). 449 
For the dissolution experiments in the absence of excipients, high variability (coefficient 450 
of variation (CV%) > 20%) was observed in some cases only at the first 3 min, and a lower 451 
variability was observed in later time points (CV% < 20%). For the dissolution experiments in 452 
excipient presence, cases of increased variability were identified (15% < CV% < 70% and 15% 453 
< CV% < 50% at early and late time points, respectively) that may relate to the heterogeneous 454 
nature of the physical mixtures (Koester et al., 2003a; Koester et al., 2003b; Zarmpi et al., 455 
2019). The preparation process of the physical mixtures could be further optimized in future 456 
studies along with the use of more replicates. 457 
3.4. Multivariate data analysis of in vitro dissolution data 458 
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The standardized coefficients of the variables for the SSG and CCS model are presented in 459 
Figure 9. The two models showed a good fit (SSG: R2 = 0.5, CCS: R2 = 0.5). For SSG, 460 
excipient brand (negative effect, p < 0.05), Drugaq.sol. (negative effect, p < 0.05) and medium 461 
(negative effect, p < 0.05) were the critical variables in the model. The negative effect of the 462 
excipient brand indicates that increasing the viscosity type of SSG resulted in less pronounced 463 
dissolution enhancement compared to the low viscosity SSG brands. Enhanced compact 464 
wetting by low viscosity SSG brands is expected due to their faster water uptake and higher 465 
swelling (Abraham et al., 2016). Formation of gelling layer by high viscosity SSG brands 466 
which delays drug dissolution (Quodbach and Kleinebudde, 2016) could also explain this 467 
finding. The impact of varying SSG viscosity was more pronounced for the poorly soluble 468 
drug, indicated by the significance of the variable Drugaq.sol. in the model, as poorly soluble 469 
drugs will benefit more by an improvement in compact wetting. The negative effect of the 470 
variable medium reveals the pronounced enhancement in drug dissolution by SSG presence in 471 
acidic compared to basic conditions (especially, for the poorly soluble drug). 472 
For CCS, excipient brand (negative effect, p < 0.05) and Drugaq.sol. (negative effect, p < 473 
0.05) were critical variables in the model. Increasing the particle size of CCS will result in less 474 
pronounced improvement in drug dissolution probably due to the formation of physical or 475 
diffusive barrier for drug dissolution by larger excipient particles. The negative effect of the 476 
variable Drugaq.sol. indicates that the improved wetting or compact disintegration by CCS 477 
presence will contribute more to the dissolution of poorly soluble drugs. The multivariate data 478 
analysis revealed that CCS variability may be critical for the initial stages of drug dissolution. 479 
4. Conclusions 480 
Superdisintegrant variability and interchangeability may be challenging for oral product 481 
performance, as the presence of superdisintegrants in pharmaceutical formulations directly 482 
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affects drug dissolution. In this study, the use of surface dissolution UV imaging allowed the 483 
semi-qualitative analysis of SSG and CCS swelling and their impact on drug dissolution. The 484 
fast swelling ability of SSG and CCS was confirmed, which depended on the critical excipient 485 
material attributes and the pH of the dissolution medium. These results reveal that SSG and 486 
CCS should not be considered interchangeable with each other in oral solid dosage forms. 487 
Presence of superdisintegrants in compacts containing highly and poorly soluble compounds 488 
resulted in significantly faster drug dissolution for both drugs probably due to the enhanced 489 
compact wetting or compact disintegration by the hydrophilic excipients. Changing excipients 490 
with varying material properties needs to be carefully consider in oral drug development as the 491 
different excipient critical material attributes affected the extent of drug dissolution 492 
(pronounced dissolution enhancement was observed by low viscosity SSG or low particle size 493 
CCS brands, especially for the poorly soluble drug). The potential biopharmaceutical 494 
implications of superdisintegrants were revealed, as in superdisintegrant presence, an interplay 495 
between drug aqueous solubility and medium characteristics was found that could affect 496 
product performance (highly soluble drug: faster drug dissolution in basic compared to acidic 497 
media due to the increased excipient hydration capacity; poorly soluble drug: slower drug 498 
dissolution in basic compared to acidic media potentially due to the presence of a swollen 499 
excipient structure on top of the compact). SSG viscosity type, CCS particle size and drug 500 
aqueous solubility were considered critical biopharmaceutical factors affecting the 501 
performance and the impact of superdisintegrant variability on drug dissolution. It is concluded 502 
that excipient variability can be challenging for oral drug performance and that 503 
biopharmaceutical considerations need to be taken into account when changes in excipient 504 
brands/grades are necessary in oral product development. Further studies to assess the impact 505 
and interplay of other superdisintegrant properties using a wide range of compounds would be 506 
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Figure captions 631 
Figure 1: Chemical structure of a. Sodium Starch Glycolate and b. Croscarmellose Sodium 632 
(ChemDraw Professional 15) 633 
Figure 2: Absorbance values (Abs) of the studied superdisintegrant types and brands as a 634 
function of distance from the center of the sample cup (mm) in 0.1 N HCl pH 1 (SDi1, 0 635 
mL/min, 37 °C, 254 nm) presented up to 2.5 min. 636 
Figure 3: Absorbance values (Abs) of the studied superdisintegrant types and brands as a 637 
function of distance from the center of the sample cup (mm) in phosphate buffer pH 6.8 (SDi1, 638 
0 mL/min, 37 °C, 254 nm) up to 2.5 min. 639 
Figure 4: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from compacts 640 
in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface dissolution UV 641 
imaging (SDi1, 1 mL/min, 37°C) in absence (control: black circles/colour) and presence of the 642 
studied SSG brands (Glycolys LV: green squares/colour, Explotab CLV: blue 643 
diamonds/colour, Glycolys: red triangles/colour). (Mean ±SD, n =3) 644 
Figure 5: a. Relative effects of excipients on the AUCs of the dissolution profiles for a. PRC 645 
and b. CBZ in presence of the studied SSG brands (Glycolys LV: green colour, Explotab CLV: 646 
blue colour, Glycolys: red colour) in 0.1 N HCl pH 1 and phosphate buffer pH 6.8. b. Relative 647 
effects of excipients on the AUCs of the dissolution profiles for a. PRC and b. CBZ in presence 648 
of the studied CCS brands (AcDiSol: blue colour, Primellose: red colour) in 0.1 N HCl pH 1 649 
and phosphate buffer pH 6.8. 650 
Figure 6: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from compacts 651 
in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface dissolution UV 652 
imaging (SDi1, 1 mL/min, 37°C) in absence (control: black circles/colour) and presence of the 653 
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studied SSG brands (Glycolys LV: green squares/colour, Explotab CLV: blue 654 
diamonds/colour, Glycolys: red triangles/colour). (Mean ±SD, n =3) 655 
Figure 7: Cumulative % dissolved (top) and dissolution rates (bottom) of PRC from compacts 656 
in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface dissolution UV 657 
imaging (SDi1, 1 mL/min, 37°C) in absence (control: black circles/colour) and presence of the 658 
studied CCS brands (AcDiSol: blue squares/colour, Primellose: red diamonds/colour). (Mean 659 
±SD, n =3) 660 
Figure 8: Cumulative % dissolved (top) and dissolution rates (bottom) of CBZ from compacts 661 
in a. 0.1 N HCl pH 1 and b. phosphate buffer pH 6.8 using real-time surface dissolution UV 662 
imaging (1 mL/min, 37°C) in absence (control: black circles/colour) and presence of the 663 
studied CCS brands (AcDiSol: blue squares/colour, Primellose: red diamonds/colour). (Mean 664 
±SD, n =3) 665 
Figure 9: Standardized coefficients corresponding to the studied variables (and their 666 
interactions) for SSG (blue colour) and CCS (red colour). * denotes coefficients with p < 0.05. 667 
(Mean, - SE) [Exc. Brand: viscosity type for SSG, particle size for CCS].668 
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